Neoleukin Therapeutics, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is Neoleukin Therapeutics, Inc.’s 10-Q for the quarter ended September 30, 2023, not a Neurogene Inc. 10-Q. Neurogene was then a private company party to a pending merger with Neoleukin.
Business context and reporting period
The filing reports unaudited third-quarter and nine-month results through September 30, 2023. Neoleukin had discontinued development of its NL-201 program, suspended research and development, and reduced its workforce in two restructurings. It was pursuing strategic alternatives, principally its proposed merger with Neurogene.
Under the July 17, 2023 merger agreement, Neurogene was to become a wholly owned subsidiary of Neoleukin. The companies anticipated closing in the fourth quarter of 2023, subject to customary conditions and stockholder approvals. Neoleukin expected to change its name to Neurogene Inc. upon closing.
Financial results and liquidity
| Metric | Three months ended September 30, 2023 | Nine months ended September 30, 2023 | Prior-year comparison |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue reported |
| Research and development expense | $0.6 million | $7.9 million | $9.5 million and $31.1 million, respectively |
| General and administrative expense | $5.0 million | $12.5 million | $4.1 million and $13.7 million, respectively |
| Total operating expenses | $5.6 million | $23.8 million | $13.6 million and $44.8 million, respectively |
| Net loss | $4.5 million | $20.8 million | $13.1 million and $44.1 million, respectively |
| Interest income | $1.0 million | $3.0 million | $0.6 million and $0.8 million, respectively |
| Net loss per share | $0.41 | $1.86 | $1.18 and $3.99, respectively |
At September 30, 2023, cash and cash equivalents were $25.2 million and short-term investments were $53.3 million, totaling approximately $78.5 million. Working capital was $74.7 million. Total assets were $89.6 million, total liabilities $14.4 million, and stockholders’ equity $75.2 million. Accumulated deficit was $471.9 million.
Operating activities used $21.4 million in cash during the first nine months of 2023, compared with $34.7 million in the prior-year period. Investing activities provided $8.7 million, principally reflecting investment maturities net of purchases and proceeds from asset sales. Financing activities used $0.4 million, primarily for finance lease payments.
The filing reports no material conventional borrowings. Lease liabilities totaled approximately $10.7 million, including $1.6 million current operating lease liabilities and $9.1 million non-current operating lease liabilities; finance lease liabilities were immaterial. No gross margin is meaningful because the company reported no product revenue.
Changes versus the prior comparable period
- Third-quarter R&D expense fell 93% year over year; nine-month R&D expense fell 75%, mainly due to the NL-201 discontinuation, suspended R&D, and workforce reductions.
- Third-quarter G&A expense rose 20%, driven mainly by merger-related legal and professional fees and an Eastlake lease impairment. Nine-month G&A expense declined 9% as reduced personnel and other costs partly offset merger costs and facility expenses.
- Nine-month net loss improved by $23.3 million year over year, reflecting lower operating expenses, partly offset by a $3.4 million property-and-equipment impairment recorded in 2023.
- Interest income increased as higher market rates increased returns on money-market funds and U.S. Treasury investments.
Outlook, risks, contingencies, and unusual items
- Management stated that available cash, cash equivalents, and short-term investments were expected to fund planned operations for at least 12 months after the filing date. This estimate is based on the current plan, which excludes resuming R&D or starting clinical trials; the filing warns that actual cash needs and runway may differ.
- If completed, the merger was expected to include a $95 million Neurogene pre-closing financing. Former Neurogene holders were projected to own approximately 84% of the combined company and legacy Neoleukin holders approximately 16%, subject to assumptions including Neoleukin’s net cash at closing. The combined company was expected to require substantial additional capital.
- If the merger does not close, Neoleukin said its board may pursue other alternatives, including another transaction, asset disposition, or winding down and dissolution. Failure to close could entail transaction costs, management disruption, and a possible stock-price decline. Under specified circumstances, Neoleukin could owe a $3.0 million termination fee and up to $1.0 million of Neurogene expense reimbursement.
- Neoleukin recorded a $3.4 million impairment charge on property and equipment in the first quarter and a $0.1 million impairment of the Eastlake lease right-of-use asset in the third quarter. It also sold property and equipment during the second quarter; the filing reports $2.1 million in sale proceeds and describes a net gain, with separate gains and losses in expense classifications.
- At September 30, restructuring liabilities accrued were $0.5 million. The company expected to pay remaining November 2022 restructuring costs by year-end 2023 and remaining March 2023 restructuring costs by the end of the first quarter of 2024. Merger-related separation benefits, retention bonuses, and third-party costs expected upon closing were not recorded in these financial statements.
- In October 2023, after quarter-end, Neoleukin entered a sublease for the Eastlake space expected to yield approximately $1.6 million of lease payments through September 2026. Also after quarter-end, 592,650 shares were issued upon exercise of pre-funded warrants for immaterial proceeds.
- A one-for-five reverse stock split took effect September 25, 2023. Neoleukin reported regaining Nasdaq’s minimum-bid-price compliance as of October 6, 2023, but warned that future compliance was not assured.
- Key risks include merger closing conditions and dilution, additional financing needs, the possibility of dissolution if no transaction succeeds, lease obligations, limited remaining personnel, and the absence of product revenue. Management reported disclosure controls were effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the merger and Neurogene’s $95 million pre-closing financing closed, and the final ownership split, exchange ratio, net-cash calculation, and any contingent value rights.
- Current cash, investment balances, operating burn, and whether the stated 12-month runway remains applicable after merger-related costs or a change in business plan.
- The combined company’s financing requirements, dilution, and development plans following the transaction.
- Actual savings and remaining liabilities from the restructurings, and the realized economics of the Eastlake sublease and other lease commitments.
- Nasdaq listing status, outstanding pre-funded warrants and equity awards, and the effect of the reverse split on share counts and ownership.